Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Kyverna is seeking a Contract Safety Writer/Scientist – Pharmacovigilance (Consultant) with deep expertise in Safety/Pharmacovigilance to support critical regulatory and medical safety documentation activities. This individual will play a key role in preparing high-quality safety regulatory documents, such as drafting responses to FDA clinical or postmarket Information Requests (IRs), supporting external advisory committee meetings, safety related clinical and medical inquiries, etc. The ideal candidate combines strong scientific writing skills with hands-on experience translating complex safety analyses into clear, regulatory-compliant documentation.
Title: Safety Writer/Scientist – Contract
Location: Remote eligible
Hourly Rate: $170/hr - $190/hr
Duration: 6+ months (20-30 hours per week)
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
